{"classes":[{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation was not calculated for 2 participants.","groupId":"OG000","spread":"NA","value":"1608"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles until disease progression or unacceptable alisertib-related toxicity (up to 3 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG000","title":"Alisertib 40 mg ECT QD 14D"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK evaluable population included all participants for whom there were sufficient dosing and alisertib concentration time data to permit non-compartmental PK analysis. Here number of participants analyzed are participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose","title":"Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14","type":"PRIMARY","unitOfMeasure":"nM"}